Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Dextrose injection in end-stage knee arthritis will cause growth of cartilage cells in a particular area of complete cartilage loss. Dextrose concentration will be 12.5%. Cartilage status will be monitored by pre and post treatment arthroscopy views with specialized (methylene blue) staining for cartilage.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidad Nacional de Rosario

Criteria

Inclusion Criteria:

• Weight ≤ 90 kilos.

• Available for clinic any day.

• Agreeable to keep coming if pain stops.

• More than one phone number.(close relative ok)

• Willing to wait 6 months prior to considering a TKA.

• Good strength in arms to help stand.

• Knee flexion more than 100 degrees.

• 90% reduction of standing, walking and sitting pain 5 minutes after intraarticular injection of 9 ml of 0.25% dextrose.

• XRay repeat with camera at knee height confirms bone on bone status in the medial compartment.

Exclusion Criteria:

• No dementia.

• No radiating back pain.

• No systemic inflammatory conditions.

• No history of knee fracture or infection.

• No cancer history.

• No blood thinners.

• No daily narcotic.

• No walking limitation from another cause.

• Repetitive squatting or stair use on job.

• Inability to use one arm to help come to stand.

• Painful hip ROM or imitative of patient's pain.

• Knee extension lacking more than 15 degrees on each side.

• Any degree of valgus.

• Varus of 20 degree or more.

• A painful Baker's cyst.

• Visible bone shift when walking

• Meniscal tear seen on arthroscopy that could block motion and needs trimming.

• Significant loose bodies seen on arthroscopy.

• Severe synovitis seen on arthroscopy.

• More than 1 outerbridge lesion in the medial compartment of the femur.